CARE App for Caregivers of Stem Cell Transplant Patients
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the effectiveness of a mobile app called the CARE app, designed to assist caregivers of patients undergoing stem cell transplants. The app aims to enhance the quality of life and overall experience for these caregivers. Participants will either use the app alongside usual care or continue with the usual care, which includes regular meetings with a social worker. Ideal participants are adult caregivers who live with or are designated to care for patients receiving stem cell transplants for cancer and can understand and speak English. As an unphased trial, this study provides caregivers the opportunity to contribute to innovative research that could improve support for others in similar situations.
Do I need to stop my current medications to join the trial?
The trial does not specify whether you need to stop taking your current medications.
What prior data suggests that the CARE app is safe for caregivers of stem cell transplant patients?
Why are researchers excited about this trial?
Researchers are excited about the CARE App for caregivers of stem cell transplant patients because it offers a new way to support caregivers during a challenging time. Unlike standard care, which mainly involves meetings with a social worker, the CARE App provides interactive modules that caregivers can use at their convenience, potentially improving their ability to manage stress and support the patient. This app could enhance the quality of care by offering easily accessible resources and tools, making the caregiving process more manageable and less stressful.
What evidence suggests that the CARE app is effective for improving the quality of life for caregivers of stem cell transplant patients?
In this trial, participants will be randomized to receive either the CARE app alongside usual care or just usual care. Research has shown that the CARE app improves the lives of those caring for stem cell transplant patients. Studies have found that the app significantly reduces stress and emotional challenges caregivers face, such as feeling overwhelmed, depressed, or experiencing symptoms similar to PTSD (post-traumatic stress disorder). It also provides support to help caregivers manage more effectively. Overall, the CARE app is a promising tool for making caregiving easier and less stressful.12346
Who Is on the Research Team?
Areej El-Jawahri, MD
Principal Investigator
Massachusetts General Hospital
Are You a Good Fit for This Trial?
This trial is for adult caregivers of cancer patients undergoing stem cell transplants. Participants must understand and speak English, as the CARE app is English-only. They should be closely involved with the patient, either living together or designated as a caregiver during transplant.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants use the CARE app and receive usual care, including meeting with a transplant social worker
Follow-up
Participants are monitored for quality of life, caregiving burden, coping, anxiety, depression, PTSD symptoms, and self-efficacy
What Are the Treatments Tested in This Trial?
Interventions
- CARE Application
- Usual Care
Trial Overview
The study tests if a mobile application called CARE can help improve life quality for caregivers by providing psychosocial support. Caregivers will use this app alongside usual care methods to see if there's any benefit over standard practices alone.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Participants randomized to the CARE app + usual care will complete the following: * Questionnaires at baseline, Day 10, Day 60, and Day 100 post-HCT * use the CARE app from enrollment up to 60 days post-HCT: the CARE app includes 5 contains 5 modules and a 6th optional module * receive usual care as per HCT practice which entails meeting with a transplant social worker prior to HCT and as needed for extra visits
Participants randomized to usual care will complete the following: * Questionnaires at baseline, Day 10, Day 60, and Day 100. * receive usual care as per HCT practice, which entails meeting with a transplant social worker prior to HCT and as needed for extra visits.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
The Leukemia and Lymphoma Society
Collaborator
Published Research Related to This Trial
Citations
BMT-CARE App: A Randomized Controlled Trial of ...
The BMT-CARE App led to significantly improved QOL, caregiving burden, depression, and PTSD symptoms among HSCT caregivers.
a study protocol for the BMT-CARE app - PMC
The study design is a non-blinded randomised controlled trial of a digital health intervention for caregivers of patients undergoing HSCT.
Mobile CARE-App to Promote Coping for Caregivers of ...
This is a randomized clinical trial to determine whether a psychosocial mobile application (CARE app) is effective at improving the quality of life and ...
Digital App Improves Caregiver Well-Being Post HSCT
The BMT-CARE App, as a psychosocial digital health intervention, effectively improves QOL and reduces psychological strain in HSCT caregivers.
5.
curetoday.com
curetoday.com/view/bmt-care-app-improves-quality-of-life-and-mental-health-for-caregiversBMT-CARE App Improves Quality of Life and Mental Health ...
BMT-CARE app boosted quality of life, lowered depression and PTSD symptoms, and improved coping mechanisms for caregivers of stem cell ...
A Mobile Health Intervention in Caregivers of Patients ...
Caregivers are essential in supporting cancer patients, especially those undergoing hematopoietic cell transplantation (HCT).
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.